Department of Biochemistry and Immunology, Lillebaelt Hospital, Vejle, Denmark.
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
Clin Chem Lab Med. 2018 Apr 25;56(5):688-701. doi: 10.1515/cclm-2017-0592.
Epidermal growth factor receptor (EGFR) serves as a co-target for dual/pan-EGFR-inhibitors in breast cancer. Findings suggest that EGFR and EGFR-ligands are involved in resistance towards certain breast cancer treatments. The aim is to explore the validity of EGFR and EGFR-ligands in blood as prognostic and predictive biomarkers in breast cancer. The systematic review was conducted in accordance to the PRISMA guidelines. Literature searches were conducted to identify publications exploring correlations between EGFR/EGFR-ligands in serum/plasma of breast cancer patients and prognostic/predictive outcome measures. Sixteen publications were eligible for inclusion. Twelve studies evaluated EGFR, whereas five studies evaluated one or more of the EGFR-ligands. Current evidence indicates associations between low baseline serum-EGFR and shorter survival or reduced response to treatment in patients with advanced breast cancer, especially in patients with estrogen and/or progesterone receptor positive tumors. The prognostic and predictive value of EGFR and EGFR-ligands in blood has only been investigated in highly selected subsets of breast cancer patients and most studies were small. This is the first systematic review evaluating the utility of EGFR and EGFR-ligands as predictive and prognostic biomarkers in blood in breast cancer. Further exploration in large well-designed studies is needed.
表皮生长因子受体（EGFR）可作为乳腺癌中双重/泛 EGFR 抑制剂的共同靶标。研究结果表明，EGFR 和 EGFR 配体参与了某些乳腺癌治疗的耐药性。本研究旨在探讨 EGFR 和 EGFR 配体在血液中作为乳腺癌预后和预测生物标志物的有效性。系统评价符合 PRISMA 指南。进行文献检索以确定探讨乳腺癌患者血清/血浆中 EGFR/EGFR 配体与预后/预测结果之间相关性的出版物。有 16 篇出版物符合纳入标准。12 项研究评估了 EGFR，而 5 项研究评估了一种或多种 EGFR 配体。目前的证据表明，基线血清 EGFR 水平低与晚期乳腺癌患者的生存时间缩短或对治疗的反应降低相关，尤其是在雌激素和/或孕激素受体阳性肿瘤患者中。EGFR 和 EGFR 配体在血液中的预后和预测价值仅在乳腺癌的高度选择亚组患者中进行了研究，并且大多数研究规模较小。这是首次系统评价评估 EGFR 和 EGFR 配体作为血液中乳腺癌预测和预后生物标志物的效用。需要在大型精心设计的研究中进一步探索。
